Author: Ravi Shankar

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

EFI and Agfa’s DPS Business to Combine and Form a Global, Full-Service Industrial Inkjet Company

Combination to Create a Broader, More Diversified Business with a Comprehensive Product Portfolio, Expanded Geographic Reach and Enhanced Capabilities to Serve Customers Across Key End Markets

Mortsel, Belgium and Londonderry, N.H. – September 28, 2026 – 7.45 a.m. CET

Electronics for Imaging, Inc. (“EFI”), a leading industrial inkjet business and portfolio company of Siris, and Agfa-Gevaert (“Agfa”) today announced a definitive agreement to combine Agfa’s Digital Printing Solutions business (“Agfa DPS”) with EFI. An affiliate of Siris will hold a 60% interest and Agfa will hold a 40% interest in the jointly held company, which will bring together the operating capabilities of EFI and Agfa DPS under a governance structure whereby Siris and Agfa will act as equal partners.

The agreement follows the global partnership EFI and Agfa established in 2024, which enabled both companies to expand their product offerings through access to complementary technologies, underscoring the value that their respective strengths, application expertise and expanded portfolios could create for customers worldwide.

The combination brings together two leading businesses with specialized technology capabilities and application focus areas to create a scaled industrial inkjet business with breadth across the fastest-growing segments of the industry. Backed by a global service network, the combined company will draw on a broader base of inkjet expertise spanning print engines, inks, software and workflow, shortening the path from development to production for customers.

EFI brings global leadership in industrial inkjet, helping customers accelerate the transition from analog to digital imaging, with particular strength in digital single pass for corrugated packaging, roll-to-roll, hybrid and textile printers through its Nozomi, VUTEK and Reggiani platforms. Agfa DPS is a leading provider of industrial inkjet solutions, with distinct strengths in display graphics, décor and packaging applications. Its recently renewed portfolio includes the Jeti TAURO, Onset PANTHERA and SpeedSet ORCA platforms. Together, EFI and Agfa DPS expect to generate approximately €540 million ($625 million) of revenue in 2026 on a pro forma basis and will serve a diversified base of thousands of customers across more than 100 countries, supported by complementary geographic strengths across North America and Europe and a global sales and service network.

The combined company is expected to have the potential to realize significant synergies over time, driven by enhanced cross-selling opportunities and the benefits of a platform with greater scale, including expanded access to new applications and geographies.

“Today’s announcement reflects our long-term commitment to digital printing and our conviction in the future of the industry,” said Pascal Juéry, CEO of Agfa-Gevaert. “By bringing together Agfa DPS and EFI, we are creating a stronger business with greater scale, broader access and enhanced innovation capabilities. Rather than continue as a standalone business, we are choosing to partner with Siris to unlock the next phase of accelerated growth for our DPS business while maintaining meaningful upside for Agfa’s stakeholders.”

“Since our investment in EFI in 2019, we have supported the company’s evolution into a focused industrial inkjet leader, drawing on our experience helping technology and industrial businesses scale,” said Frank Baker, Co-Founder and Managing Partner, and David Calamai, Managing Director, of Siris. “EFI and Agfa DPS bring together distinct and complementary capabilities, forming a business with the reach and depth to do more for customers across more markets. We look forward to partnering with Agfa to accelerate innovation and expansion for customers worldwide.”

“At Agfa, we believe this combination can help accelerate the adoption of digital printing across the industry,” said Vincent Wille, President of Agfa DPS. “By combining technology leadership, global reach and deep application expertise, we can help our customers achieve new levels of productivity, agility and sustainable growth, enabling them to innovate faster, reduce waste and create lasting value across the entire print ecosystem.”

“Our partnership with Agfa over the past two years has highlighted the strength of our complementary technologies, expertise and teams,” said Frank Pennisi, CEO of EFI. “This combination is a natural next step that allows us to build on that momentum with a broader platform, accelerating innovation and expanding the solutions we can deliver to customers across industrial inkjet.”

The proposed transaction is expected to close by the end of 2026 and is subject to customary employee information and consultation processes, regulatory approvals and closing conditions.

EFI and Siris were advised by DC Advisory, which acted as exclusive financial advisor, and Sidley Austin LLP, which served as legal advisor.

About EFI
EFI™ is a global technology company focused on advancing the transformation from analog to digital imaging. The company has a scalable portfolio of products, solutions, services and support for the manufacturing of signage, packaging, textiles and other industrial printing applications. EFI’s offerings include a wide range of printers, inks, digital front ends and workflow software designed to help customers increase profits, improve productivity and optimize production workflows. www.efi.com

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of €1.1 billion. Through its Digital Printing Solutions (DPS) business unit, Agfa provides cutting-edge inkjet printing solutions—equipment, consumables, software and services—designed for high-quality, efficient production in the sign & display and packaging market, as well as a broad range of industrial markets. www.agfa.com

About Siris
Siris is a leading private equity firm focused on control investments in services businesses that enable transformative technologies to scale. The firm invests in companies that support the underlying infrastructure for these technologies and help enterprises integrate them into critical operational workflows. Based in West Palm Beach, Florida, Siris has deployed more than $9 billion of equity capital since inception. www.siris.com

Contact:
EFI
Holly O’Rourke
Corporate Communications
+1 (603)-475-9244
e-mail: holly.orourke@efi.com

Agfa-Gevaert
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Siris
Kate Kelley / Madeline Jones / Woomi Yun
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
e-mail: Siris-JF@joelefrank.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the proposed combination of Electronics for Imaging, Inc. (“EFI”) and Agfa-Gevaert’s Digital Printing Solutions business (“Agfa DPS”), the anticipated timing of completion of the transaction, including the expectation that it will close by the end of 2026, expected synergies and other benefits of the transaction, and the future operations, business prospects, financial performance and performance of the combined company. Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “will,” “may,” “could,” “should,” “would,” “potential” and similar expressions.

These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results and developments to differ materially. Such risks and uncertainties include, among others, the ability to obtain required regulatory approvals; the completion of customary employee information and consultation processes; the satisfaction of other closing conditions; the possibility that the transaction may be delayed or not completed on the anticipated terms or timeline; the ability of EFI, Agfa-Gevaert and Siris to realize the anticipated benefits and synergies; risks associated with integrating the businesses, technologies, operations, employees, systems and customer and supplier relationships of EFI and Agfa DPS; business disruption and the retention of key personnel; and changes in market conditions, customer demand, competition, economic conditions or other factors affecting the industrial inkjet industry and the combined company.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are not guarantees of future performance. Neither EFI, Agfa-Gevaert nor Siris, nor, following completion of the transaction, the combined company, undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise, except as may be required by applicable law.

Attachment

• press release in pdf

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Agfa-Gevaert NV extends revolving credit facility

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV has extended its 180 million euro revolving credit facility to August 1, 2030. Under the previous agreement, it was scheduled to mature on August 1, 2028. The facility is used for working capital and general corporate purposes.

The financial covenants included in the facility are now:

Leverage ratio covenant: Net financial debt*/Adj. EBITDA** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): maximum 3.0
Interest coverage ratio covenant: adjusted EBITDA/interest expense** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): minimum 4.0
Liquidity headroom covenant: cash and cash equivalents plus headroom under the Facilities (tested quarterly): minimum 30 million euro

The applicable financial indicators and required covenant levels are disclosed with the quarterly results publication and are tested quarterly or semi-annually following the requirement of the facility agreement.

The facility is now also secured by a pledge of the Agfa HealthCare shares.

The revolving credit facility has been arranged by a club of 4 financial institutions: BNP Paribas Fortis SA/NV, KBC Bank NV, Belfius Bank SA/NV and ING Belgium SA/NV.

*Net financial debt excl IFRS 16: the sum of non-current and current liabilities to banks excluding non-current and current lease liabilities and excluding pension debt, including bank overdrafts minus cash and cash equivalents.
**Adjusted EBITDA: the result from continuing operating activities before depreciation, amortization, restructuring expenses and adjustments.

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

• press release in pdf

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Agfa-Gevaert NV extends revolving credit facility

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV has extended its 180 million euro revolving credit facility to August 1, 2030. Under the previous agreement, it was scheduled to mature on August 1, 2028. The facility is used for working capital and general corporate purposes.

The financial covenants included in the facility are now:

Leverage ratio covenant: Net financial debt*/Adj. EBITDA** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): maximum 3.0
Interest coverage ratio covenant: adjusted EBITDA/interest expense** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): minimum 4.0
Liquidity headroom covenant: cash and cash equivalents plus headroom under the Facilities (tested quarterly): minimum 30 million euro

The applicable financial indicators and required covenant levels are disclosed with the quarterly results publication and are tested quarterly or semi-annually following the requirement of the facility agreement.

The facility is now also secured by a pledge of the Agfa HealthCare shares.

The revolving credit facility has been arranged by a club of 4 financial institutions: BNP Paribas Fortis SA/NV, KBC Bank NV, Belfius Bank SA/NV and ING Belgium SA/NV.

*Net financial debt excl IFRS 16: the sum of non-current and current liabilities to banks excluding non-current and current lease liabilities and excluding pension debt, including bank overdrafts minus cash and cash equivalents.
**Adjusted EBITDA: the result from continuing operating activities before depreciation, amortization, restructuring expenses and adjustments.

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

• press release in pdf

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated, previous announcement	2,020,805	949.93	1,919,619,024
21 September 2026	10,310	1.112.06	11,465,359
22 September 2026	10,712	1.111.08	11,901,844
23 September 2026	10,162	1.102.36	11,202,133
24 September 2026	10,480	1.099.58	11,523,602
25 September 2026	10,408	1.109.31	11,545,709
Accumulated under the programme	2,072,877	953.87	1,977,257,671

Following settlement of the transactions stated above, Jyske Bank will own a total of 2,072,877 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.56% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
                                                         
Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42

Attachment

• Share repurchase programme 20260928

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated, previous announcement	2,020,805	949.93	1,919,619,024
21 September 2026	10,310	1.112.06	11,465,359
22 September 2026	10,712	1.111.08	11,901,844
23 September 2026	10,162	1.102.36	11,202,133
24 September 2026	10,480	1.099.58	11,523,602
25 September 2026	10,408	1.109.31	11,545,709
Accumulated under the programme	2,072,877	953.87	1,977,257,671

Following settlement of the transactions stated above, Jyske Bank will own a total of 2,072,877 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.56% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
                                                         
Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42

Attachment

• Share repurchase programme 20260928

• €11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026
• The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection points
• In this context, publication of first half 2026 financial results is postponed
• Enrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis now estimated for early-2027 due to a lower number of death events than expected
• Subcutaneous formulation of lusvertikimab (IL-7R) on track for validation by mid-2027
• Opportunity to move lusvertikimab into Phase 2 with current IV formulation in chronic pouchitis in 2027

Nantes, France, September 28, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today reported its cash position as of June 30, 2026, updated its financial calendar and provided a business update.

“On the operational front, enrolment of Tedopi’s Phase 3 trial ARTEMIA in non-small cell lung cancer is on track. The interim futility analysis for ARTEMIA is event-driven. Deaths across the study have accrued more slowly than originally projected, and the analysis is now expected in early-2027, which is definitely interesting. In parallel, the subcutaneous formulation of lusvertikimab is moving as planned and results should be available by mid-2027 to support pursuing clinical development in ulcerative colitis. We are also very encouraged by our conversations with key opinion leaders to move rapidly into a Phase 2 trial with the current formulation in Chronic Pouchitis, a significant unmet need”, commented Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics. “We have been actively engaging with institutional investors in the United States and in Europe for the past few months, helped by a flexible bridge financing in May, and are confident that the strength of our pipeline provides a solid foundation as we work to secure the financing needed to reach key value inflection points.”

Cash Position as of June 30, 2026

As of June 30, 2026, OSE Immunotherapeutics’ cash position totalled €11.1 million, compared to €17.0 million as of March 31, 2026. 

The Company implemented a flexible bridge equity financing in May 2026 which, in addition to available cash, and based on its current plans, is estimated to be sufficient to fund its operations through December 2026. This cash runway does not include any potential future milestone payments from existing partnerships.

This bridge financing was the first step of a global financing strategy aiming at securing OSE’s 3-year Strategic Plan and the Company continues to actively engage with institutional investors in the United States and in Europe in view to further extend its runway beyond 2026.

In addition, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, restructuring of its existing debt, and potential milestone payments from current partnerships.

In the context of its ongoing financing efforts, the Company has deferred the publication of its half-year financial statements for 2026 and its Interim Financial Report to a later date.

Pivotal Phase 3 clinical trial ARTEMIA of Tedopi® in second-line non-small cell lung cancer (NSCLC)

Enrolment in the international pivotal Phase 3 clinical trial ARTEMIA evaluating Tedopi® in 363 HLA-A2 positive patients with metastatic NSCLC who have developed secondary resistance to immune checkpoint inhibitors is on track for completion by end of December 2026, as planned.

As per protocol, a futility analysis will be conducted independently by the statisticians of the Independent Data Monitoring Committee (IDMC). This analysis, performed when the trial reaches a predefined number of events, is based on an interim survival analysis and will remain blinded to the Sponsor, Regulatory Authorities, and all Investigators.

Initial assumptions anticipated reaching the required and predefined number of deaths by Q3 2026. While enrolment of the study has progressed according to plan, the trial is showing a lower number of deaths than initially expected, and the Company now anticipates reaching the predefined number of death events by the end of 2026. Consequently, the futility analysis is now expected to take place early 2027.

Other clinical trials evaluating Tedopi® in multiple indications

TEDOVA in ovarian cancer

In May 2026, the Company reported positive topline results from the TEDOVA/GINECO-OV244b/ENGOT-ov58 academic, international, Phase 2 trial sponsored by ARCAGY-GINECO and evaluating Tedopi®, with or without pembrolizumab, as a maintenance treatment in 185 patients with platinum-sensitive recurrent ovarian cancer (PSOC).

The primary endpoint was progression-free survival (PFS) comparing Tedopi® combined with pembrolizumab and the best supportive care. It was met and results showed a statistically significant improvement in PFS for the combination of Tedopi® and pembrolizumab compared to best supportive care (median PFS: 4.1 months vs 2.8 months; HR=0.53; p<0.001). When comparing the two investigational arms, the addition of pembrolizumab to Tedopi® resulted in a 28% reduction in the risk of progression or death (HR=0.72, p=0.074).

These results were presented by principal investigator Alexandra Leary, MD, PhD, at the ASCO 2026 Annual Meeting in May 2026 in Chicago, United States.

Combi-TED in NSCLC

Topline results from the Combi-TED Phase 2 international clinical trial sponsored by FoRT and evaluating Tedopi® in second-line treatment in combination with anti-PD1 or chemotherapy in 105 patients with metastatic NSCLC will be presented by principal investigator Federico Cappuzzo, MD, PhD, at the ESMO 2026 Annual Meeting on October 25, 2026, in Madrid, Spain.

Subcutaneous formulation of lusvertikimab (IL-7R) in inflammatory bowel diseases (IBD)

The subcutaneous formulation of lusvertikimab to be advanced in clinical development was selected and characterized earlier this year. The achieved concentration at 225mg per mL, based on previously evaluated intravenous efficacious doses in Phase 2 of 450mg and 850mg, is potentially compatible with the use of an autoinjector device.

The application for authorization of a Phase I study in healthy volunteers is currently being prepared with a submission scheduled by the end of 2026, with results expected by mid-2027.

ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on LinkedIn.

Contacts

OSE Immunotherapeutics: investors@ose-immuno.com

FP2COM (Media Relations): Florence Portejoie: fportejoie@fp2com.fr I +33 6 07 768 283

Astr Partners (Investor Relations):

Europe/UK: Guillaume Cabon: guillaume.cabon@astrpartners.com I +33 6 95 06 92 06

United States: Brian korb: brian.korb@astrpartners.com I +1 917-653-5122

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. 

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on June 4, 2026, including the annual financial report for the fiscal year 2025, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Attachment

• EN_260928_OSE_Immunotherapeutics_2026_Q2_Cash_and_Business_Update_vdef

• €11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026
• The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection points
• In this context, publication of first half 2026 financial results is postponed
• Enrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis now estimated for early-2027 due to a lower number of death events than expected
• Subcutaneous formulation of lusvertikimab (IL-7R) on track for validation by mid-2027
• Opportunity to move lusvertikimab into Phase 2 with current IV formulation in chronic pouchitis in 2027

Nantes, France, September 28, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today reported its cash position as of June 30, 2026, updated its financial calendar and provided a business update.

“On the operational front, enrolment of Tedopi’s Phase 3 trial ARTEMIA in non-small cell lung cancer is on track. The interim futility analysis for ARTEMIA is event-driven. Deaths across the study have accrued more slowly than originally projected, and the analysis is now expected in early-2027, which is definitely interesting. In parallel, the subcutaneous formulation of lusvertikimab is moving as planned and results should be available by mid-2027 to support pursuing clinical development in ulcerative colitis. We are also very encouraged by our conversations with key opinion leaders to move rapidly into a Phase 2 trial with the current formulation in Chronic Pouchitis, a significant unmet need”, commented Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics. “We have been actively engaging with institutional investors in the United States and in Europe for the past few months, helped by a flexible bridge financing in May, and are confident that the strength of our pipeline provides a solid foundation as we work to secure the financing needed to reach key value inflection points.”

Cash Position as of June 30, 2026

As of June 30, 2026, OSE Immunotherapeutics’ cash position totalled €11.1 million, compared to €17.0 million as of March 31, 2026. 

The Company implemented a flexible bridge equity financing in May 2026 which, in addition to available cash, and based on its current plans, is estimated to be sufficient to fund its operations through December 2026. This cash runway does not include any potential future milestone payments from existing partnerships.

This bridge financing was the first step of a global financing strategy aiming at securing OSE’s 3-year Strategic Plan and the Company continues to actively engage with institutional investors in the United States and in Europe in view to further extend its runway beyond 2026.

In addition, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, restructuring of its existing debt, and potential milestone payments from current partnerships.

In the context of its ongoing financing efforts, the Company has deferred the publication of its half-year financial statements for 2026 and its Interim Financial Report to a later date.

Pivotal Phase 3 clinical trial ARTEMIA of Tedopi® in second-line non-small cell lung cancer (NSCLC)

Enrolment in the international pivotal Phase 3 clinical trial ARTEMIA evaluating Tedopi® in 363 HLA-A2 positive patients with metastatic NSCLC who have developed secondary resistance to immune checkpoint inhibitors is on track for completion by end of December 2026, as planned.

As per protocol, a futility analysis will be conducted independently by the statisticians of the Independent Data Monitoring Committee (IDMC). This analysis, performed when the trial reaches a predefined number of events, is based on an interim survival analysis and will remain blinded to the Sponsor, Regulatory Authorities, and all Investigators.

Initial assumptions anticipated reaching the required and predefined number of deaths by Q3 2026. While enrolment of the study has progressed according to plan, the trial is showing a lower number of deaths than initially expected, and the Company now anticipates reaching the predefined number of death events by the end of 2026. Consequently, the futility analysis is now expected to take place early 2027.

Other clinical trials evaluating Tedopi® in multiple indications

TEDOVA in ovarian cancer

In May 2026, the Company reported positive topline results from the TEDOVA/GINECO-OV244b/ENGOT-ov58 academic, international, Phase 2 trial sponsored by ARCAGY-GINECO and evaluating Tedopi®, with or without pembrolizumab, as a maintenance treatment in 185 patients with platinum-sensitive recurrent ovarian cancer (PSOC).

The primary endpoint was progression-free survival (PFS) comparing Tedopi® combined with pembrolizumab and the best supportive care. It was met and results showed a statistically significant improvement in PFS for the combination of Tedopi® and pembrolizumab compared to best supportive care (median PFS: 4.1 months vs 2.8 months; HR=0.53; p<0.001). When comparing the two investigational arms, the addition of pembrolizumab to Tedopi® resulted in a 28% reduction in the risk of progression or death (HR=0.72, p=0.074).

These results were presented by principal investigator Alexandra Leary, MD, PhD, at the ASCO 2026 Annual Meeting in May 2026 in Chicago, United States.

Combi-TED in NSCLC

Topline results from the Combi-TED Phase 2 international clinical trial sponsored by FoRT and evaluating Tedopi® in second-line treatment in combination with anti-PD1 or chemotherapy in 105 patients with metastatic NSCLC will be presented by principal investigator Federico Cappuzzo, MD, PhD, at the ESMO 2026 Annual Meeting on October 25, 2026, in Madrid, Spain.

Subcutaneous formulation of lusvertikimab (IL-7R) in inflammatory bowel diseases (IBD)

The subcutaneous formulation of lusvertikimab to be advanced in clinical development was selected and characterized earlier this year. The achieved concentration at 225mg per mL, based on previously evaluated intravenous efficacious doses in Phase 2 of 450mg and 850mg, is potentially compatible with the use of an autoinjector device.

The application for authorization of a Phase I study in healthy volunteers is currently being prepared with a submission scheduled by the end of 2026, with results expected by mid-2027.

ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on LinkedIn.

Contacts

OSE Immunotherapeutics: investors@ose-immuno.com

FP2COM (Media Relations): Florence Portejoie: fportejoie@fp2com.fr I +33 6 07 768 283

Astr Partners (Investor Relations):

Europe/UK: Guillaume Cabon: guillaume.cabon@astrpartners.com I +33 6 95 06 92 06

United States: Brian korb: brian.korb@astrpartners.com I +1 917-653-5122

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. 

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on June 4, 2026, including the annual financial report for the fiscal year 2025, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Attachment

• EN_260928_OSE_Immunotherapeutics_2026_Q2_Cash_and_Business_Update_vdef

Winterthur, Switzerland, 28. September 2026 – Burckhardt Compression has secured an order from MTU Maintenance Berlin-Brandenburg for the supply of two high-speed compressor solutions at the company’s gas turbine test facility in Ludwigsfelde, Germany.

The compressor solution has been specifically designed to meet the demanding reliability requirements of the application. As part of its maintenance, repair and overhaul (MRO) services for industrial gas turbine engines (IGT), MTU Maintenance Berlin-Brandenburg conducts performance tests following engine shop visits. MTU’s test facility currently operates with natural gas and is being prepared for future operation with blends of natural gas and hydrogen of up to 25%, supporting the industry’s transition towards lower-carbon energy systems.

The location south of the German capital is the MTU network’s MRO specialist for GE Aerospace’s LM^TM-Series IGTs and in the middle of construction of a brand-new, state-of-the-art production building to accommodate the growth in maintenance demand. By supporting the reliable operation of gas turbine fleets, MTU contributes to energy security and grid stability in Europe, where flexible gas-fired power generation plays an important role in balancing fluctuations from renewable energy sources.

“Reliable gas turbine infrastructure remains essential for ensuring security of supply while supporting the energy transition,” says Andreas Brautsch, President of Burckhardt Compression’s Systems Division. “We are proud to support MTU with a solution that combines operational reliability with future readiness. This project demonstrates how Burckhardt Compression helps customers address today’s energy challenges while preparing for tomorrow’s requirements.”

The order was awarded following close collaboration between Burckhardt Compression and MTU throughout the project development phase. Burckhardt Compression’s integrated solution combines compressor technology, system expertise, service capabilities and local project execution to meet the customer’s operational requirements.

Attachment

• Fully balanced high-speed compressors

Winterthur, Switzerland, 28. September 2026 – Burckhardt Compression has secured an order from MTU Maintenance Berlin-Brandenburg for the supply of two high-speed compressor solutions at the company’s gas turbine test facility in Ludwigsfelde, Germany.

The compressor solution has been specifically designed to meet the demanding reliability requirements of the application. As part of its maintenance, repair and overhaul (MRO) services for industrial gas turbine engines (IGT), MTU Maintenance Berlin-Brandenburg conducts performance tests following engine shop visits. MTU’s test facility currently operates with natural gas and is being prepared for future operation with blends of natural gas and hydrogen of up to 25%, supporting the industry’s transition towards lower-carbon energy systems.

The location south of the German capital is the MTU network’s MRO specialist for GE Aerospace’s LM^TM-Series IGTs and in the middle of construction of a brand-new, state-of-the-art production building to accommodate the growth in maintenance demand. By supporting the reliable operation of gas turbine fleets, MTU contributes to energy security and grid stability in Europe, where flexible gas-fired power generation plays an important role in balancing fluctuations from renewable energy sources.

“Reliable gas turbine infrastructure remains essential for ensuring security of supply while supporting the energy transition,” says Andreas Brautsch, President of Burckhardt Compression’s Systems Division. “We are proud to support MTU with a solution that combines operational reliability with future readiness. This project demonstrates how Burckhardt Compression helps customers address today’s energy challenges while preparing for tomorrow’s requirements.”

The order was awarded following close collaboration between Burckhardt Compression and MTU throughout the project development phase. Burckhardt Compression’s integrated solution combines compressor technology, system expertise, service capabilities and local project execution to meet the customer’s operational requirements.

Attachment

• Fully balanced high-speed compressors

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, September 28, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.

“The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its merger with Supernus Pharmaceuticals, providing a valuable asset for Addex and solidifying our leading portfolio of drug candidates targeting GABAB receptor biology. Our spin-out company, Neurosterix made as well great progress and is on track to complete its Phase 1 clinical study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, during the fourth quarter of 2026,” said Tim Dyer, CEO of Addex.

Operating Highlights:

• Raised USD 2.8 million (CHF 2.2 million) through At the Market (ATM) offering agreement with H.C Wainwright & Co
• Regained rights to GABAB positive allosteric modulator portfolio from Indivior
• Spin-out company, Neurosterix continued to progress through Phase 1 clinical development with the M4 PAM candidate, NTX-253
• Continued advancing GABAB PAM chronic cough candidate through preclinical development

Key H1 2026 Financial Data

CHF’ thousands	Q2 26	Q2 25	Change	H1 26	H1 25	Change
Income	10	36	(26)	18	107	(89)
R&D expenses	(38)	(234)	196	(74)	(391)	317
G&A expenses	(617)	(535)	(82)	(1,069)	(1,056)	(13)
Total operating loss	(645)	(733)	88	(1,125)	(1,339)	214
Finance result, net	2	6	(4)	–	(13)	13
Share of net loss of associates	(1,102)	(1,232)	130	(2,331)	(2,079)	(252)
Net loss from continuing operations	(1,745)	(1,959)	213	(3,456)	(3,432)	(24)
Net profit from discontinued operations	–	118	(118)	–	118	(118)
Net loss for the period	(1,745)	(1,841)	95	(3,456)	(3,314)	(142)
Basic and diluted net loss per share	(0.01)	(0.02)	0.01	(0.03)	(0.03)	–
Net decrease in cash during the period	(168)	(524)	356	(872)	(1,041)	169
Cash and cash equivalents as of June 30	767	2,301	(1,534)	767	2,301	(1,534)
Shareholders’ equity	1,909	7,213	(5,304)	1,909	7,213	(5,304)

Financial Summary:

Income, primarily related to the fair value of the services received from Neurosterix’s Group at zero cost, decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.

R&D expenses decreased by CHF 0.3 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025, primarily due to decreased GABAB PAM outsourced R&D expenses and reduced services received at zero cost from Neurosterix’s Group.

G&A expenses, primarily driven by staff costs and professional fees, remained stable around CHF 1.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.

The net result decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025, primarily due to reduced R&D expenses partially offset by an increased share of the net loss of Neurosterix’s Group.

Basic and diluted loss per share remained stable at CHF 0.03 per share for the six-month periods ended June 30, 2026 and 2025.

Cash and cash equivalents decreased to CHF 0.8 million at June 30, 2026, compared to CHF 2.3 million at June 30, 2025. The decrease of CHF 1.5 million between June 30, 2026, and June 30, 2025, is primarily due to operating activities partially offset by the sale of treasury shares and ADSs.

Post balance sheet event: From July 1, 2026 to August 25, 2026, the Group sold 52,970,533 shares at an average price of CHF 0.043 (USD 0.053) for total gross proceeds of CHF 2.3 million (USD 2.8 million).

2026 Half-Year Consolidated Financial Statements:
The 2026 Half-Year financial report can be found on the Company’s website in the investor/download section here.

Conference Call Details:
A conference call will be held today, on September 28, 2026, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science, will deliver a brief presentation followed by a Q&A session.

Joining the Conference Call:

1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
2. In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link: Registration webcast

Conference call registration link: Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.                                       

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.
  
Contacts: 

Tim Dyer  Chief Executive Officer  Telephone: +41 22 884 15 55  PR@addextherapeutics.com

Mike Sinclair  Partner, Halsin Partners  +44 (0)7968 022075  msinclair@halsin.com

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.